Adrian Bot – författare

This volume presents the critical information attendant to developing vaccines using the genetic basis of immunology. The authors explore which techniques and experimental paths can be pursued so that efficacious results in human trials can be reasonably expected for the treatment of bacterial, fungal, viral, and autoimmune diseases, as well as cancers. A chapter on the genetic vaccination of neonates with virus or plasmid DNA is also included.

Recent advances in immunology and biology have opened new horizons in cancer therapy, included in the expanding array of cancer treatment options, which are immunotherapies, or cancer vaccines, for both solid and blood borne cancers. Cancer Vaccines: Challenges and Opportunities in Translation is the first text in the field to bring immunotherapy treatments from the laboratory trial to the bedside for the practicing oncologist.Cancer Vaccines: Challenges and Opportunities in Translation:Critically analyzes the most promising classes of investigational immunotherapies, integrating their scientific rationale and clinical potentialDiscusses "theranostics" as pertaining to immunotherapy, i.e., using molecular diagnostics to identify patients that would most likely benefit from a therapyPresents the new paradigm of biomarker guided R&D and clinical development in immunotherapy of cancerReviews bottlenecks in translational process of immunotherapies and offers strategies to resolve them

Depending on the definition of this concept that is adopted, adolescence is the narrow threshold or a vast no-man's land that separates adulthood from childhood. In one -physica1ist- view, adolescence begins when secondary sex characters become noticeable and ends when they are fully developed. In another -socio1ogica1- view, adolescence ends when social independence has been gained. It may easily take many years more to span the interval between those two events. In this collection of papers by specialists from various disciplines, physical, psychological and social aspects of adolescence are considered. The book originates from a postgraduate course for medical practitioners, who deal with adolescents, but the range of the papers is such that we hope it may be of value to a much wider readership, including educators and all who are concerned with adolescents. The course was entitled: 'Adolescence: psychological, social and biological aspects', and was held in Leiden in November 1981. It was the fourth in a series of Boerhaave Courses instigated by the Dutch Growth Foundation of available. which a published record has now become Previous titles are 'Somatic growth of the child' (1966), 'De samenstel1ing van het mense1ijk 1ichaam' (1968) (=Human body composition), and 'Normal and abnormal development of brain and behaviour' (1971).VI The detailed programme of the course was planned by Dr. F.J. Bekker, Prof. Dr. J.L. van den Brande, Prof. Dr. W. Everaerd, Prof. A.Th. Schweizer and Prof. Dr. J.J. van der Werff ten Bosch.

Recent advances in immunology and biology have opened new horizons in cancer therapy, included in the expanding array of cancer treatment options, which are immunotherapies, or cancer vaccines, for both solid and blood borne cancers. Cancer Vaccines: From Research to Clinical Practice is the first text in the field to bring immunotherapy treatments from the laboratory trial to the bedside for the practicing oncologist.Cancer Vaccines: From Research to Clinical Practice:Analyzes the most promising classes of investigational immunotherapies, integrating their scientific rationale and clinical potentialDiscusses "theranostics" as pertaining to immunotherapy, i.e., using molecular diagnostics to identify patients that would most likely benefit from a therapyPresents the new paradigm of biomarker guided R&D and clinical development in immunotherapy of cancerReviews bottlenecks in translational process of immunotherapies and offers strategies to resolve them

Recent advances in immunology and biology have opened new horizons in cancer therapy, included in the expanding array of cancer treatment options, which are immunotherapies, or cancer vaccines, for both solid and blood borne cancers. Cancer Vaccines: Challenges and Opportunities in Translation is the first text in the field to bring immunotherapy treatments from the laboratory trial to the bedside for the practicing oncologist.Cancer Vaccines: Challenges and Opportunities in Translation:Critically analyzes the most promising classes of investigational immunotherapies, integrating their scientific rationale and clinical potentialDiscusses "theranostics" as pertaining to immunotherapy, i.e., using molecular diagnostics to identify patients that would most likely benefit from a therapyPresents the new paradigm of biomarker guided R&D and clinical development in immunotherapy of cancerReviews bottlenecks in translational process of immunotherapies and offers strategies to resolve them

This book presents the critical information attendant to developing vaccines using the genetic basis of immunology. The authors explore which techniques and experimental paths can be pursued so that efficacious results in human trials can be reasonably expected for the treatment of bacterial, fungal, viral, and autoimmune diseases, as well as cancers. A chapter on the genetic vaccination of neonates with virus or plasmid DNA is also included.

Recent advances in immunology and biology have opened new horizons in cancer therapy, included in the expanding array of cancer treatment options, which are immunotherapies, or cancer vaccines, for both solid and blood borne cancers. Cancer Vaccines: From Research to Clinical Practice is the first text in the field to bring immunotherapy treatments from the laboratory trial to the bedside for the practicing oncologist.Cancer Vaccines: From Research to Clinical Practice:Analyzes the most promising classes of investigational immunotherapies, integrating their scientific rationale and clinical potentialDiscusses "theranostics" as pertaining to immunotherapy, i.e., using molecular diagnostics to identify patients that would most likely benefit from a therapyPresents the new paradigm of biomarker guided R&D and clinical development in immunotherapy of cancerReviews bottlenecks in translational process of immunotherapies and offers strategies to resolve them